In Federal Trade Commission v. Actavis Inc., the U.S. Supreme Court made a watershed recognition that will drastically affect a common practice in the pharmaceutical industry. The court held that a practice known as reverse settlement or reverse payment, in which the plaintiff pays the defendant, is not immune from antitrust laws, even if the patent holder’s conduct falls within the exclusionary scope of the patent.
This ruling certainly will lead to an increase in antitrust challenges to reverse settlements in pharmaceutical-related patent litigation. The court’s ruling also is likely to spill into other areas where antitrust law and patent law converge, as a basis to challenge the inherent “monopoly” granted to patent holders.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]